PD Dr. Andreas Kremer

Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Biochemie und Molekulare Pathobiologie

Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis (2019) Kremer A, Bowlus C, Bedossa P, Pares A, Forman L, Drenth JP, Ryder S, et al. Conference contribution Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy (2019) Bowlus CL, Pockros PJ, Kremer A, Pares A, Forman LM, Drenth JPH, Ryder S, et al. Conference contribution Chronischer Pruritus (2019) Kremer A Journal article, Review article Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus (2019) Pogatzki-Zahn EM, Pereira MP, Cremer A, Zeidler C, Dreyer T, Riepe C, Wempe C, et al. Journal article Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial (2019) Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, et al. Journal article Pruritus bei systemischen Erkrankungen (2019) Kremer A, Mettang T Journal article, Review article A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats (2019) Einer C, Leitzinger C, Lichtmannegger J, Eberhagen C, Rieder T, Borchard S, Wimmer R, et al. Journal article PU.1 controls fibroblast polarization and tissue fibrosis (2019) Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici AB, Weber S, et al. Journal article Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution International experience of vedolizumab in primary sclerosis cholangitis and inflammatory bowel disease (2018) Williamson K, Lytvyak E, Kremer A, De Krijger M, Trivedi P, Estes D, Yu L, et al. Conference contribution